Pharmacological Profiling and Therapeutic Evaluation of Herbal Plants in Inflammatory Bowel Disease Management

Abstract

The objective of this research is to evaluate the effectiveness of combination therapy involving Trimetazidine with beta blockers, such as Metoprolol, in managing anginal episodes, given the limitations of traditional hemodynamic agents in treating all individuals with anginal problems. While medications like nitrates, beta-adrenergic antagonists, and calcium channel blockers are commonly used to reduce myocardial oxygen demand and alleviate cardiac strain, they often produce undesirable hemodynamic effects such as changes in blood pressure, heart rate, and cardiac output. Consequently, a significant proportion of patients continue to experience chronic angina despite treatment, increasing the risk of future heart issues.

Several clinical studies, including the Total Ischemic Burden European Trial (TIBET), International Multicenter Angina Exercise (IMAGE) study, Combination of Trimetazidine with Metoprolol in stable effort Angina, Poland (TRIMPOL II) study, and Trimetazidine in Angina Combination Therapy (TACT) study, have reported conflicting findings regarding the efficacy of combination therapy with two hemodynamic agents. However, previous research suggests that combining Trimetazidine with beta blockers or long-acting nitrates can lead to significant improvements in exercise stress test parameters and better management of uncontrolled anginal symptoms, with good patient tolerability.

This study aims to explore the potential of metabolic therapy, exemplified by the combination of Trimetazidine with Metoprolol, as a contemporary approach to ischemic illnesses. The lack of unique dosage forms and comprehensive research investigations underpinning this combination make them promising candidates for further investigation in this study.